South Korea’s GC Biopharma Corp. broke ground on Wednesday on Indonesia’s first blood product plant through technology transfer.
Indonesian pharmaceutical companies PT Triman and PT Medquest Jaya Global held a groundbreaking ceremony for the blood product factory in Jababeka Industrial Estate, 35 km east of Jakarta, on the previous day.
The plant will be constructed with transferred technologies from GC Biopharma. It aims to process up to 400,000 liters of raw plasma annually on a 40,000-square-meter site, targeting operation by 2027.
GC Biopharma obtained approval from the Indonesian Ministry of Health in June this year for the construction and technology transfer related to the blood product plant.
It signed a three-party agreement with the Indonesian Red Cross Society and the two pharmaceutical companies in Indonesia.
GC Biopharma previously exported a blood product plant to Thailand for the first time among domestic pharmaceutical firms.
Write to Ji-Hyun Lee at bluesky@hankyung.com
South Korea's GC Biopharma Corp. announced on Thursday that its flu vaccine GC Flu secured a $10 million order in the upcoming bid by Thailand's Government Pharmaceutical Organization (GPO) next year.Since entering the Thai flu vaccine market in 2014, this is the largest supply for GC Biopharm
South Korea's GC Biopharma Corp. announced on Wednesday that its quadrivalent influenza vaccine "GC Flu Quadrivalent" has received approval from Egyptian health regulatory authorities.This is the first approval for this product in the African continent. According to the company, Egypt is one o
Huh Eun-chul, CEO of GC Biopharma (left) and Marcelo Rodolfo Hahn, CEO of Blau Farmacêutica South Korea's GC Biopharma Corp. on Monday announced on Monday that it has a supply contract with Blau Farmacêutica, a Brazilian pharmaceutical firm, for its IVIG-SN 5% blood product. Th
South Korea's GC Biopharma Corp. announced on Thursday that it will start developing a flu vaccine based on messenger ribonucleic acid (mRNA).The drug maker said it has exercised an option contract with Acuitas Therapeutics, a Canadian pharma that specializes in lipid nano particle (LNP) deliv
South Korea's GC Biopharma Corp. is set to regain the No. 1 spot in global production of chickenpox vaccines after earning qualification to enter the World Health Organization (WHO) procurement market with Barycela following its export hit Suduvax. This breakthrough is expected to heat up glob